CoChat
Sign Up
Cited by 10Chronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseasesCystic Fibrosis Research Advances

Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study

Esposito, Antonietta, Valentino, Maria Rosaria, Bruzzese, Dario, Bocchino, Marialuisa, Ponticiello, Antonio, Stanziola, Anna, Sanduzzi, Alessandro·2016·Pulmonary Pharmacology & Therapeutics
DOI 10.1016/j.pupt.2016.03.003
Open this paper in CoChat — free account

Abstract

Background Chronic Obstructive Pulmonary Disease (COPD) is a chronic and progressive lung disease characterized by irreversible airflow obstruction, airway inflammation, oxidative stress and, often, mucus hypersecretion. The aim of this study is to determine if carbocisteine, a mucolytic and antioxidant agent, administered daily for 12 months, can reduce exacerbation frequency in COPD patients.Methods This observational study was conducted in Naples (population approximately 1000,000), Italy. It included 85 out-patients (mean age of 67.8 ± 8.6 years) followed by Clinic of Respiratory Diseases of the University Federico II. Every patient underwent spirometry demonstrating airflow obstruction not fully reversible according to ERS/ATS criteria for COPD diagnosis (Tiffenau index less than 70% after administration of salbutamol, a beta2 agonist drug). Patients enrolled had diagnosed COPD since 2 years and suffered at least one exacerbation in the previous year. None of the patients had been treated with carbocisteine or other mucolytic agent for a longer period of time than 7 days and no more than 4 times in the previous year to the enrollment. All of them assumed daily 2.7 g of carbocisteine lysine salt for a year in addition to their basic therapy.Results The comparison of exacerbation frequency between the previous year (T0) and the end of study treatment (T12), documents a statistically significant reduction of exacerbations(number of exacerbations at T0: 2 [1,3] vs number of exacerbations at T12: 1 [1,2]; p < 0.001).Quality of life was also reported and showed a statistically significant improvement at the end of the study (p < 0.001).We did not find correlation between reducing exacerbation frequency and exposure to cigarette smoking, passive smoking exposure in childhood, the use of inhaled steroids, the level of education of our patients and the GOLD stadium.Interpretation Daily administration of a mucolytic drug such as carbocisteine for prolonged periods in addition to the bronchodilator therapy can be considered a good strategy for reducing exacerbation frequency in COPD.

Integrity signals

Registry

Crossref · 10.1016/j.pupt.2016.03.003

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • One year of treatment with carbocisteine resulted in a decreased number of respiratory exacerbations and significantly improved quality of life.

    “Several observational studies confirmed that one year of treatment with carbocisteine resulted in a decreased number of respiratory exacerbations and significantly improved quality of life (Esposito et al. 2016).”

    From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Esposito et al. 2016

Cites

Flagged first, then by citations

1 of the 18 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Esposito, A., Valentino, M. R., Bruzzese, D., Bocchino, M., Ponticiello, A., Stanziola, A., & Sanduzzi, A.
Affiliations
  • Federico II University Hospital (IT)
  • University of Naples Federico II (IT)
Corresponding author
Esposito, Antonietta
ORCID
Venue
Pulmonary Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2016-04
Volume
37
Pages
85-88
ISSN
1094-5539 (ISSN-L)
DOI
10.1016/j.pupt.2016.03.003
OpenAlex
W2296100280
Cited by
10
References
18
Citations by year
2025: 2 · 2023: 2 · 2022: 2 · 2018: 3 · 2017: 1
FWCI
1.19
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Pulmonary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Keywords
carbocisteine, chronic obstructive pulmonary disease, COPD exacerbation prevention, mucolytic agents, antioxidant therapy, quality of life, airflow obstruction, GOLD staging, tobacco smoke exposure, inhaled corticosteroids
MeSH terms
Aged, Bronchodilator Agents, Carbocysteine, Expectorants, Female, Humans, Italy, Male, Middle Aged, Quality of Life, Smoking, Spirometry, Time Factors, Pulmonary Disease, Chronic Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review